SVB Wealth’s Vir Biotechnology VIR Stock Holding History

SVB Wealth’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-163	Closed	-$1.06K	–	1590
2025 Q1	$1.06K	Buy	+163	New	+$1.45K	﹤0.01%	1344

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SVB Wealth's VIR Position: Q2 2025 in Review

SVB Wealth sold out of Vir Biotechnology (VIR) in Q2 2025, closing a stake of 163 shares — an estimated $1.06K sold.

SVB Wealth first reported a position in VIR in Q1 2025 and held it in 1 quarter. The position peaked at $1.06K in Q1 2025. 213 funds tracked by Wall St. Rank hold VIR as of Q2 2025.

SVB Wealth reported no remaining Vir Biotechnology position as of Q2 2025 after selling out during the quarter.
SVB Wealth sold 163 Vir Biotechnology shares in Q2 2025, an estimated $1.06K.
SVB Wealth first reported a position in Vir Biotechnology in Q1 2025 and held it in 1 quarter.
SVB Wealth's Vir Biotechnology position peaked at $1.06K in Q1 2025.
213 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2025.

Based on SVB Wealth's 13F filing for Q2 2025, filed 14 Aug 2025.